Impaired innate host defense causes susceptibility to respiratory virus infections in cystic fibrosis.
Viral infection is the primary cause of respiratory morbidity in cystic fibrosis (CF) infants. Here, we identify that host factors allow increased virus replication and cytokine production, providing a mechanism for understanding the severity of virus disease in CF. Increased virus is due to lack of nitric oxide synthase 2 (NOS2) and 2', 5' oligoadenylate synthetase (OAS) 1 induction in response to virus or IFNgamma. This can be attributed to impairment of activation of signal transducer and activator of transcription (STAT)1, a fundamental component to antiviral defense. NO donor or NOS2 overexpression provides protection from virus infection in CF, suggesting that NO is sufficient for antiviral host defense in the human airway and is one strategy for antiviral therapy in CF children.
Zheng
Shuo
S
Department of Pulmonary and Critical Care Medicine, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
De
Bishnu P
BP
Choudhary
Suresh
S
Comhair
Suzy A A
SA
Goggans
Tannishia
T
Slee
Roger
R
Williams
Bryan R G
BR
Pilewski
Joseph
J
Haque
S Jaharul
SJ
Erzurum
Serpil C
SC
D000998:Antiviral Agents / Q000494:pharmacology; D003550:Cystic Fibrosis / Q000150:complications / Q000276:immunology* / Q000821:virology*; D004198:Disease Susceptibility / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate / Q000276:immunology*; D066298:In Vitro Techniques; D007372:Interferons / Q000494:pharmacology; D020030:Nitric Oxide Donors / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000235:genetics / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D010224:Parainfluenza Virus 3, Human; D010253:Respirovirus Infections / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D014157:Transcription Factors / Q000378:metabolism
D000998:Antiviral Agents; D020030:Nitric Oxide Donors; D014157:Transcription Factors; D007372:Interferons; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II